David E. Cohen
CIK: 0001347383
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Evommune, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 2, 2026EVMN
Evommune, Inc.
Sale(S)Direct5.5K shares at avg. $20.21$110K - Jun 2, 2026EVMN
Evommune, Inc.
Sale(S)Direct600 shares at avg. $21.38$13K - Jun 2, 2026EVMN
Evommune, Inc.
Award(A)DirectStock Option (Right to buy)
15.7K shares- - Nov 7, 2025EVMN
Evommune, Inc.
Conversion(C)Direct6.1K shares- - Nov 5, 2025EVMN
Evommune, Inc.
Award(A)DirectStock Option (Right to Buy)
38K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 2, 2026 | EVMN Evommune, Inc. | Sale(S) | 5,456 | $20.21 | $110,266 | Direct |
| Jun 2, 2026 | EVMN Evommune, Inc. | Sale(S) | 600 | $21.38 | $12,828 | Direct |
| Jun 2, 2026 | EVMN Evommune, Inc. | Award(A) Stock Option (Right to buy) | 15,673 | - | - | Direct |
| Nov 7, 2025 | EVMN Evommune, Inc. | Conversion(C) | 6,056 | - | - | Direct |
| Nov 5, 2025 | EVMN Evommune, Inc. | Award(A) Stock Option (Right to Buy) | 37,960 | - | - | Direct |
1-5 of 5 transactions
About Cohen David E
Cohen David E (SEC CIK 0001347383) files insider reports with the SEC as Director of Evommune, Inc. (EVMN).
Signal8 holds 4 ownership filings by Cohen David E (1 Form 3, 3 Form 4), filed between Nov 5, 2025 and Jun 3, 2026. Those filings report 5 transactions, from Nov 5, 2025 to Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cohen David E's filings is in PALO ALTO, CA.
Recent filings by Cohen David E
Other insiders filing for Evommune, Inc. (EVMN)
- Pena Luis C., President & CEO
- Carver Kyle, Chief Financial Officer
- KIRSCH ARTHUR S, Director
- Drew Janice Suzann, Chief of Dev. Operations
- Patel Jeegar Pravinkumar, Chief Scientific Officer
- MCGRAW BENJAMIN F III, Director